Outcome | Cohort B | Cohort A | ||
---|---|---|---|---|
n | M (SD) | n | M (SD) | |
Psychiatric symptoms | ||||
 BSI | ||||
  Baseline | 78 | 67.9 (11.9) | 102 | 63.7 (11.7) |
  6-weeks (mid-treatment) | 40 | 67.4 (10.1) | 62 | 55.2 (14.0) |
  12-weeks (end-of-treatment) | 28 | 62.6 (12.4) | 21 | 50.9 (13.5) |
  6-months | 27 | 67.8 (11.9) |  |  |
  12-months | 24 | 68.6 (11.5) |  |  |
Substance use | ||||
 BSCQ | ||||
  Baseline | 77 | 45.0 (24.8) | 102 | 45.8 (23.5) |
  6-weeks (mid-treatment) | 40 | 67.0 (22.7) | 63 | 67.3 (20.2) |
  12-weeks (end-of-treatment) | 28 | 65.0 (29.5) | 7 | 74.4 (22.3) |
  6-months | 27 | 50.1 (28.6) |  |  |
  12-months | 24 | 54.3 (31.6) |  |  |
 SDS | ||||
  Baseline | 76 | 9.5 (3.0) |  |  |
  6-weeks (mid-treatment) | 40 | 7.7 (3.3) |  |  |
  12-weeks (end-of-treatment) | 28 | 8.6 (4.0) |  |  |
  6-months | 27 | 5.0 (3.5) |  |  |
  12-months | 24 | 5.7 (5.0) |  |  |
Quality of life | ||||
 QOL | ||||
  Baseline | 79 | 3.2 (0.8) |  |  |
  6-weeks (mid-treatment) | 40 | 3.6 (0.6) |  |  |
  12-weeks (end-of-treatment) | 26 | 3.7 (0.7) |  |  |
  6-months | 27 | 3.2 (0.7) |  |  |
  12-months | 24 | 3.4 (0.7) |  |  |